Improving Telemedicine Helps to Minimise Risks for Cancer Patients
With Rafal Dziadziuszko, Medical University of Gdansk, Poland
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Extension of Indications for Brentuximab Vedotin
New indication concerns the treatment of previously untreated systemic anaplastic large cell lymphoma
COVID-19 Infection and Related Challenges in Aviano Cancer Centre in Italy
Situation in the first half of March 2020
EMA Recommends Granting a Marketing Authorisation for Isatuximab
It is intended for the treatment of multiple myeloma
Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors
Results from an observational study conducted during the influenza season 2018/2019
Findings from a Retrospective Case Study of COVID-19 Infection in Cancer Patients in Wuhan: An Emphasis on Severe Events
Analysis of risk factors associated with admission to an intensive care unit, the use of mechanical ventilation or death
Life Expectancy of Adult Survivors of Childhood and Adolescent Cancer
Findings from a simulation model-based approach
Splitting Healthcare Teams May Help to Reduce Disruption in Patient Care
With Ross Soo, National University Cancer Institute Singapore (NCIS), Singapore.
Subcutaneous Daratumumab Is Not Inferior To Intravenous In Relapsed Or Refractory Multiple Myeloma
Results from the COLUMBIA study
PSMA PET-CT is a Suitable Replacement for Conventional Imaging in High-Risk Localised Prostate Cancer
It provides superior accuracy to combined CT and bone scan findings
EMA Starts Review of Handling Errors with Depot Formulations of Leuprorelin Medicines
Handling errors during preparation and administration can cause that some patients receive insufficient amount of medicine
Selumetinib Shows Durable Tumour Shrinkage and Clinical Benefit in Neurofibromatosis
MEK inhibition is a rational treatment strategy for neurofibromatosis type 1–related tumours